Theratechnologies Inc (NASDAQ: THTX) has experienced a decline in its stock price by -9.32 compared to its previous closing price of 1.59. However, the company has seen a fall of -16.76% in its stock price over the last five trading days. globenewswire.com reported 2025-01-09 that MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that a shortage of EGRIFTA SV ® (tesamorelin for injection) will occur at the patient level in mid-January 2025, following a voluntary shutdown of the contract manufacturing facility in 2024. While the Company is aware of remaining inventory of EGRIFTA SV ® in certain pharmacies throughout the United States, several pharmacies have reported stockouts.
Is It Worth Investing in Theratechnologies Inc (NASDAQ: THTX) Right Now?
The 36-month beta value for THTX is at 1.27. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for THTX is 19.10M, and currently, shorts hold a 0.43% of that float. The average trading volume for THTX on January 31, 2025 was 98.74K shares.
THTX’s Market Performance
THTX’s stock has seen a -16.76% decrease for the week, with a -19.55% drop in the past month and a 14.29% gain in the past quarter. The volatility ratio for the week is 5.98%, and the volatility levels for the past 30 days are at 6.71% for Theratechnologies Inc The simple moving average for the past 20 days is -18.43% for THTX’s stock, with a 4.52% simple moving average for the past 200 days.
Analysts’ Opinion of THTX
Many brokerage firms have already submitted their reports for THTX stocks, with Cantor Fitzgerald repeating the rating for THTX by listing it as a “Overweight.” The predicted price for THTX in the upcoming period, according to Cantor Fitzgerald is $9 based on the research report published on November 17, 2022 of the previous year 2022.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see THTX reach a price target of $3, previously predicting the price at $8. The rating they have provided for THTX stocks is “Hold” according to the report published on July 29th, 2021.
THTX Trading at -9.01% from the 50-Day Moving Average
After a stumble in the market that brought THTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.94% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 5.98%, as shares sank -20.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.01% upper at present.
During the last 5 trading sessions, THTX fell by -16.76%, which changed the moving average for the period of 200-days by +1.41% in comparison to the 20-day moving average, which settled at $1.7654. In addition, Theratechnologies Inc saw -20.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for THTX
Current profitability levels for the company are sitting at:
- 0.12 for the present operating margin
- 0.77 for the gross margin
The net margin for Theratechnologies Inc stands at -0.04. The total capital return value is set at 0.59.
Based on Theratechnologies Inc (THTX), the company’s capital structure generated 1.52 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at -2.94. The interest coverage ratio of the stock is 0.92.
Currently, EBITDA for the company is -10.31 million with net debt to EBITDA at 1.91. When we switch over and look at the enterprise to sales, we see a ratio of 1.06. The receivables turnover for the company is 8.17for trailing twelve months and the total asset turnover is 1.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
In conclusion, Theratechnologies Inc (THTX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
